MedTrace Logo

BAL Fluid Biomarkers in Sarcoma

NCT06815666 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-03-04

No results posted yet for this study

Summary

This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.

Conditions

  • Soft Tissue Sarcoma (STS)
  • Bronchoalveolar Lavage (BAL)
  • Bronchoalveolar Lavage Fluid

Interventions

PROCEDURE

Bronchoscopy & Metastasectomy

Routine bronchoscopy and standard of care metastasectomy

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-29
Primary Completion
2032-04-01
Completion
2032-04-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06815666 on ClinicalTrials.gov